Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Assessing the Concordance of Preclinical and Clinical Results in the Testing of New Drug Interventions for Parkinson’s Disease and Epilepsy
EF 2014-15
Résumé
Although basic research has greatly improved our understanding of many diseases, successful translation of this knowledge into new treatments for patients is lagging behind. Of all new interventions entering clinical trials, only 11% are approved; this number is even lower for agents addressing neurological conditions (8%). Such low approval rates mean that most clinical trial participants are exposed to the risks of testing novel compounds without their contribution being justified by the development of new treatments for future patients. One reason for this very low rate of translation may be that the animal (preclinical) studies are poorly performed and so do not accurately predict the effect the drug will have on humans. If this is the case, money and animal lives are being wasted to produce inaccurate results that lead clinicians to expose patients to drugs that ultimately won't work. To address this important issue, my project will assess how well preclinical models predict the results we see in human studies of all Parkinson's and epilepsy drugs that reached Phase III clinical testing between 2005 and 2012. I will also determine whether any study design factors (i.e. randomization of animals to control or treatment arms) make the more carefully performed preclinical studies better predictors of the true clinical effects. To do so, I will use systematic review and meta-analysis: I will extract key results from all the preclinical and clinical literature on the drugs in my cohort, compile them and compare them. The results of my thesis will provide an evidence base for creating guidelines to improve preclinical research and will help maximize the utility of animal and human studies in the endeavour to find cures for these devastating diseases.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
331346
Name
Hakala Amanda K
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessing the Concordance of Preclinical and Clinical Results in the Testing of New Drug Interventions for Parkinson’s Disease and Epilepsy
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinical Trials; Drug Development; Epilepsy; Experimental Medicine; Improving Preclinical Research; Medical Ethics; Neurology; Parkinson'S Disease; Systematic Review And Meta-Analysis; Translational Research
Abstract
Although basic research has greatly improved our understanding of many diseases, successful translation of this knowledge into new treatments for patients is lagging behind. Of all new interventions entering clinical trials, only 11% are approved; this number is even lower for agents addressing neurological conditions (8%). Such low approval rates mean that most clinical trial participants are exposed to the risks of testing novel compounds without their contribution being justified by the development of new treatments for future patients. One reason for this very low rate of translation may be that the animal (preclinical) studies are poorly performed and so do not accurately predict the effect the drug will have on humans. If this is the case, money and animal lives are being wasted to produce inaccurate results that lead clinicians to expose patients to drugs that ultimately won't work. To address this important issue, my project will assess how well preclinical models predict the results we see in human studies of all Parkinson's and epilepsy drugs that reached Phase III clinical testing between 2005 and 2012. I will also determine whether any study design factors (i.e. randomization of animals to control or treatment arms) make the more carefully performed preclinical studies better predictors of the true clinical effects. To do so, I will use systematic review and meta-analysis: I will extract key results from all the preclinical and clinical literature on the drugs in my cohort, compile them and compare them. The results of my thesis will provide an evidence base for creating guidelines to improve preclinical research and will help maximize the utility of animal and human studies in the endeavour to find cures for these devastating diseases.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hakala, Amanda K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~